Elite Pharma gets FDA nod for generic Vyvanse; $4.3B market

ELITE PHARMACEUTICALS INC /NV/

Received FDA approval on November 15, 2024 for ANDA for generic Lisdexamfetamine Dimesylate (Vyvanse) in 7 strengths (10-70 mg capsules).
Product indicated for ADHD; marketed under Elite Laboratories label.
IQVIA reported annual sales of $4.3B for brand and generic market (12 months ending September 2024).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.